Determination That REVIA (Naltrexone Hydrochloride) Tablets, 50 Milligrams Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

[Federal Register Volume 91, Number 73 (Thursday, April 16, 2026)]
[Notices]
[Pages 20471-20472]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2026-07451]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2025-P-4151]


Determination That REVIA (Naltrexone Hydrochloride) Tablets, 50 
Milligrams Was Not Withdrawn From Sale for Reasons of Safety or 
Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) has 
determined that REVIA (naltrexone hydrochloride) tablets, 50 milligrams 
(mg), was not withdrawn from sale for reasons of safety or 
effectiveness. This determination means that FDA will not begin 
procedures to withdraw approval of abbreviated new drug applications 
(ANDAs) that refer to this drug product, and it will allow FDA to 
continue to approve ANDAs that refer to the product as long as they 
meet relevant legal and regulatory requirements.

FOR FURTHER INFORMATION CONTACT: Molly Arndt, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, Rm. 6281, Silver Spring, MD 20993-0002, 240-
402-6919, molly.arndt@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Section 505(j) of the Federal Food, Drug, 
and Cosmetic Act (FD&C Act) (21 U.S.C. 355(j)) allows the submission of 
an ANDA to market a generic version of a previously approved drug 
product. To obtain approval, the ANDA applicant must show, among other 
things, that the generic drug product: (1) has the same active 
ingredient(s), dosage form, route of administration, strength, 
conditions of use, and (with certain exceptions) labeling as the listed 
drug, which is a version of the drug that was previously approved, and 
(2) is bioequivalent to the listed drug. ANDA applicants do not have to 
repeat the extensive clinical testing otherwise necessary to gain 
approval of a new drug application (NDA).
    Section 505(j)(7) of the FD&C Act requires FDA to publish a list of 
all approved drugs. FDA publishes this list as part of the ``Approved 
Drug Products With Therapeutic Equivalence Evaluations,'' which is 
known generally as the ``Orange Book.'' Under FDA regulations, drugs 
are removed from the list if the Agency withdraws or suspends approval 
of the drug's NDA or ANDA for reasons of safety or effectiveness or if 
FDA determines that the listed drug was withdrawn from sale for reasons 
of safety or effectiveness (21 CFR 314.162).
    A person may petition the Agency to determine, or the Agency may 
determine on its own initiative, whether a listed drug was withdrawn 
from sale for reasons of safety or effectiveness. This determination 
may be made at any time after the drug has been withdrawn from sale, 
but must be made prior to approving an ANDA that refers to the listed 
drug (Sec.  314.161 (21 CFR 314.161)). FDA may not approve an ANDA that 
does not refer to a listed drug.
    REVIA (naltrexone hydrochloride) tablets, 50 mg, is the subject of 
NDA 018932, held by Teva Women's Health, Inc., and initially approved 
on November 20, 1984. REVIA is indicated for the treatment of alcohol 
dependence and for the blockade of the effects of exogenously 
administered opioids.
    In a letter dated May 16, 2018, Teva Women's Health, Inc. requested 
withdrawal of NDA 018932 for REVIA (naltrexone hydrochloride) tablets, 
50 mg. In the Federal Register of April 1, 2019 (84 FR 12262), FDA 
announced that it was withdrawing approval of NDA 018932, effective May 
1, 2019.
    Hyman, Phelps & McNamara, P.C., submitted a citizen petition dated 
September 22, 2025 (Docket No. FDA-2025-P-4151), under 21 CFR 10.30, 
requesting that the Agency determine whether REVIA (naltrexone 
hydrochloride) tablets, 50 mg, was withdrawn from sale for reasons of 
safety or effectiveness.
    After considering the citizen petition and reviewing Agency records 
and based on the information we have at this time, FDA has determined 
under Sec.  314.161 that REVIA (naltrexone hydrochloride) tablets, 50 
mg, was not withdrawn for reasons of safety or effectiveness. The 
petitioner has identified no data or other information suggesting that 
REVIA (naltrexone hydrochloride) tablets, 50 mg, was withdrawn for 
reasons of safety or effectiveness. We have carefully reviewed our 
files for records concerning the withdrawal of REVIA (naltrexone 
hydrochloride) tablets, 50 mg, from sale. We have also independently 
evaluated relevant literature and data for possible postmarketing 
adverse events. We have

[[Page 20472]]

reviewed the available evidence and determined that this drug product 
was not withdrawn from sale for reasons of safety or effectiveness.
    Accordingly, the Agency will continue to list REVIA (naltrexone 
hydrochloride) tablets, 50 mg, in the ``Discontinued Drug Product 
List'' section of the Orange Book. The ``Discontinued Drug Product 
List'' delineates, among other items, drug products that have been 
discontinued from marketing for reasons other than safety or 
effectiveness. FDA will not begin procedures to withdraw approval of 
approved ANDAs that refer to this drug product. Additional ANDAs for 
this drug product may also be approved by the Agency as long as they 
meet all other legal and regulatory requirements for the approval of 
ANDAs. If FDA determines that labeling for this drug product should be 
revised to meet current standards, the Agency will advise ANDA 
applicants to submit such labeling.

Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2026-07451 Filed 4-15-26; 8:45 am]
BILLING CODE 4164-01-P